FLT3 and acute myeloid leukemia: A first in human phase I trial of TP-0903 is planned to open in late 2016 in patients with advanced solid tumors with future clinical development aimed towards patients with ibrutinib-resistant CLL and FLT3 inhibitor-resistant AML [97,101].